Emerging Controversies in the Treatment of Osteoarthritis in Older Individuals

Consultant Pharmacist

Volumn 19, Issue 2, 2004, Pages 135-142

  Delafuente, Jeffrey C ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Acetaminophen; Nonsteroidal anti inflammatory drugs; Osteoarthritis

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB;

AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EDEMA; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; KNEE OSTEOARTHRITIS; MEDLINE; OSTEOARTHRITIS; PEPTIC ULCER; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; ULCER PERFORATION;

EID: 1042278716     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2004.135     Document Type: Review

References (25)

1. Delafuente JC. Arthritis. In: Delafuente JC, Stewart RB, eds. Therapeutics in the elderly. 3rd ed. Cincinnati, OH: Harvey Whitney Books Co; 2001.
2. Hamerman D. The biology of osteoarthritis. N Engl J Med 1989;320:1322-30.
3. Bradley JD, Brandt KD, Katz BP et al. Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991;325:87-91.
4. Felson DT. Osteoarthritis: the disease and its prevalence and impact. Ann Intern Med 2000;133:637-9.
5. Pelletier JP, Martel-Pelletier J, Howell DS. Etiopathogenesis of osteoarthritis. In: Koopman WJ, ed. Arthritis and allied conditions. A textbook of rheumatology. 13th ed. Baltimore, MD: Williams & Wilkins; 1997.
6. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis: part I. osteoarthritis of the hip. Arthritis Rheum 1995;38:1535-40.
7. Hochberg MC, Altman RD, Brandt KD et al. Guidelines for the medical management of osteoarthritis: part II. osteoarthritis of the knee. Arthritis Rheum 1995;38:1541-6.
8. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000;43:1905-15.
9. Pincus T, Koch GG, Sokka T et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001;44:1587-98.
10. Amadio P Jr, Cummings DM. Evaluation of acetaminophen in the management of osteoarthritis of the knee. Curr Ther Res 1983;4:59-66.
11. Case JP, Baliumas AJ, Block JA. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis. A randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 2003;163:169-78.
12. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal anti-inflammatory drug or pure analgesic. J Rheumatol 1992;19:1950-4.
13. Bradley JD, Katz BP, Brandt KD. Severity of knee pain does not predict a better response to an anti-inflammatory dose of ibuprofen than to analgesic therapy in patients with osteoarthritis. J Rheumatol 2001;28:1073-6.
14. Williams HJ, Ward JR, Egger MJ et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum 1993;36:1196-1206.
15. Geba GP, Weaver AL, Polis AB et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 2002;287:64-71.
16. Felson DT. The verdict favors nonsteroidal antiinflammatory drugs for treatment of osteoarthritis and a plea for more evidence on other treatments. Arthritis Rheum 2001;44:1477-80.
17. Griffin MR, Piper JM, Daugherty JR et al. Nonsteroidal anti-inflammatory drug use and increased risk of peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
18. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988;109:359-63.
19. Hernandez-Diaz S, Rodriques LAG. Association between nonsteroidal antiinflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-9.
20. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
21. Scheiman J, Isenberg J. Agents used in the prevention and treatment of nonsteroidal anti-inflammatory drug-associated symptoms and ulcers. Am J Med 1998;105:s32-s38.
22. Rich M, Scheiman JM. Nonsteroidal anti-inflammatory drug gastropathy at the new millennium: mechanisms and prevention. Semin Arthritis Rheum 2000;30: 167-79.
23. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
24. Langman MJ, Jensen DM, Watson DJ et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
25. Celebrex package insert. G. D. Searle, LLC, August 2002.